选择性化学抑制PGC-1α 糖原性活性 改善2型糖尿病
Kfir Sharabi1, Hua Lin2, Clint D J Tavares1
1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
Cell
|March 25, 2017
概括
研究人员确定了一种小分子SR-18292,该分子向PGC-1α乙化以减少葡萄糖的产生. 通过改善葡萄糖平衡和胰岛素敏感性,这种新方法对治疗2型糖尿病 (T2D) 是有前途的.
科学领域:
- 代谢疾病
- 分子生物学
- 药物发现
背景情况:
- 二型糖尿病 (T2D) 是一个全球性流行病,需要新的治疗策略.
- 抑制肝脏葡萄糖产量 (HGP) 是一种已验证的糖尿病治疗方法.
- 已知PGC-1α乙化是一种肝脏葡萄糖生成的抑制剂.
研究的目的:
- 识别用于T2D治疗的增强PGC-1α乙化的小分子.
- 研究向肝脏PGC-1α乙化的治疗潜力.
主要方法:
- 开发了一个高通量选平台来测量细胞中的PGC-1α乙化.
- 确定了增加PGC-1α乙化,抑制葡萄糖生成基因和减少肝细胞的葡萄糖输出的小分子.
- 在T2D小鼠模型中选择和测试SR-18292.
主要成果:
- SR-18292增加了PGC-1α乙化,抑制了葡萄糖基因表达,并降低了肝细胞中的葡萄糖产生.
- 在T2D小鼠模型中,SR-18292治疗降低了血糖水平.
- SR-18292显著改善了肝脏的胰岛素敏感性和葡萄糖平衡.
结论:
- 针对PGC-1α乙化是一种新型的治疗策略.
- 在临床前模型中,SR-18292显示出有效性,这表明它具有作为T2D药物的潜力.
- 了解PGC-1α调节可以了解葡萄糖代谢和糖尿病治疗.
相关概念视频
Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
Dipeptidyl Peptidase 4 Inhibitors
814
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
814
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
701
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
701
Oral Hypoglycemic Agents: Biguanides and Glitazones
755
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
755
GPCRs Regulate Adenylyl Cylase Activity
7.9K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.9K
Diabetes Mellitus: Type 2 and Gestational
5.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.2K


